You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博騰股份(300363.SZ):擬與點石化醫、廣陽灣基金及新天投資共同出資設立MAH基金
格隆匯 10-22 20:56

格隆匯10月22日丨博騰股份(300363.SZ)公佈,結合藥品上市許可持有人(MAH)制度相關政策規定,為充分發揮公司在高難複雜製劑領域的研發優勢,助力公司製劑事業部業務拓展,加快匹配公司原料藥(API)到製劑CDMO一體化的戰略訴求,同時推動重慶醫藥醫療產業快速高質量發展,公司擬與重慶點石化醫股權投資基金管理有限公司(“點石化醫”)、重慶廣陽灣綠色產業發展股權投資基金合夥企業(有限合夥)(“廣陽灣基金”)、重慶化醫新天投資集團有限公司(“新天投資”)共同出資設立重慶長生勝合醫藥私募股權投資基金合夥企業(有限合夥)(暫定名,最終以工商核准登記的名稱為準,“MAH基金”或“基金”),重點投資於高難複雜製劑領域內在關鍵中間體、API、製劑等環節具有生產成本優勢或技術壁壘的MAH公司。公司作為基金的有限合夥人之一,擬認繳出資額1.225億元,佔基金認繳出資總額的35%

公司作為有限合夥人參與此次基金投資,主要是藉助專業投資機構優勢,通過專業化投資管理團隊,投資新設或現有的具有發展潛力及競爭力產研管線的MAH 公司,充分發揮公司在高難複雜製劑領域的研發優勢,支持公司製劑事業部拓展業務,加快匹配公司從API 到製劑一體化CDMO 業務的戰略訴求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account